USE OF THE SOLUBLE FORM OF AXL IN THE DIAGNOSIS AND/OR PROGNOSIS OF HEART FAILURE SYNDROME

摘要

The present invention refers to a method for diagnosing and/or prognosing a heart failure syndrome (HF), which comprises the step of measuring, in vitro, the amount of the soluble form of AXL (sAXL) in a test sample. The invention furthermore provides methods for deciding or recommending whether to initiate a medical regimen, as well as for determining the efficacy of said medical regimen. The invention also provides the use of sAXL as a marker for the diagnosis and/or prognosis of HF sAXL is stable in serum and is differentially expressed in controls and people suffering from HF.